Celldex Therapeutics, Inc. announced that the company has hired Theresa LaVallee, Ph.D., to the newly created position of Senior Vice President, Regulatory and Precision Medicine. Dr. LaVallee was previously Senior Vice President, Translational Medicine and Product Development at Kolltan Pharmaceuticals, which Celldex recently acquired. Dr. LaVallee brings more than 15 years of industry experience in discovery and development of drug candidates in oncology and inflammation, including extensive global regulatory experience and expertise in translational medicine to enable science-driven drug development. Dr. LaVallee joined Kolltan in 2013, most recently serving as Senior Vice President, Translational Medicine and Product Development, and was responsible for developing and executing the research and development strategy. Prior to Kolltan, Dr. LaVallee held increasingly senior level roles at MedImmune/AstraZeneca and EntreMed.